JP2016530285A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016530285A5 JP2016530285A5 JP2016539372A JP2016539372A JP2016530285A5 JP 2016530285 A5 JP2016530285 A5 JP 2016530285A5 JP 2016539372 A JP2016539372 A JP 2016539372A JP 2016539372 A JP2016539372 A JP 2016539372A JP 2016530285 A5 JP2016530285 A5 JP 2016530285A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- cancer
- compound
- item
- compound according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000001875 compounds Chemical class 0.000 claims description 62
- 125000000217 alkyl group Chemical group 0.000 claims description 22
- 206010060862 Prostate cancer Diseases 0.000 claims description 20
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 20
- 102000001307 androgen receptors Human genes 0.000 claims description 19
- 108010080146 androgen receptors Proteins 0.000 claims description 19
- 239000008194 pharmaceutical composition Substances 0.000 claims description 18
- 239000000203 mixture Substances 0.000 claims description 17
- 206010028980 Neoplasm Diseases 0.000 claims description 10
- 125000004448 alkyl carbonyl group Chemical group 0.000 claims description 10
- 230000000694 effects Effects 0.000 claims description 9
- 208000002874 Acne Vulgaris Diseases 0.000 claims description 6
- 201000004384 Alopecia Diseases 0.000 claims description 6
- 206010006187 Breast cancer Diseases 0.000 claims description 6
- 208000026310 Breast neoplasm Diseases 0.000 claims description 6
- 206010014733 Endometrial cancer Diseases 0.000 claims description 6
- 206010014759 Endometrial neoplasm Diseases 0.000 claims description 6
- 206010020112 Hirsutism Diseases 0.000 claims description 6
- 206010033128 Ovarian cancer Diseases 0.000 claims description 6
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 6
- 208000004337 Salivary Gland Neoplasms Diseases 0.000 claims description 6
- 206010061934 Salivary gland cancer Diseases 0.000 claims description 6
- 206010000496 acne Diseases 0.000 claims description 6
- 206010064930 age-related macular degeneration Diseases 0.000 claims description 6
- 201000011510 cancer Diseases 0.000 claims description 6
- 229910052799 carbon Inorganic materials 0.000 claims description 6
- 208000024963 hair loss Diseases 0.000 claims description 6
- 230000003676 hair loss Effects 0.000 claims description 6
- 238000003384 imaging method Methods 0.000 claims description 6
- 208000002780 macular degeneration Diseases 0.000 claims description 6
- 208000025661 ovarian cyst Diseases 0.000 claims description 6
- 201000010065 polycystic ovary syndrome Diseases 0.000 claims description 6
- 230000002028 premature Effects 0.000 claims description 6
- 210000002307 prostate Anatomy 0.000 claims description 6
- 208000002320 spinal muscular atrophy Diseases 0.000 claims description 6
- -1 n - butyl Chemical group 0.000 claims description 5
- 206010036590 Premature baby Diseases 0.000 claims description 4
- BMQGVNUXMIRLCK-OAGWZNDDSA-N cabazitaxel Chemical compound O([C@H]1[C@@H]2[C@]3(OC(C)=O)CO[C@@H]3C[C@@H]([C@]2(C(=O)[C@H](OC)C2=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=3C=CC=CC=3)C[C@]1(O)C2(C)C)C)OC)C(=O)C1=CC=CC=C1 BMQGVNUXMIRLCK-OAGWZNDDSA-N 0.000 claims description 4
- 229960001573 cabazitaxel Drugs 0.000 claims description 4
- 239000003814 drug Substances 0.000 claims description 4
- 239000003937 drug carrier Substances 0.000 claims description 4
- 229960005386 ipilimumab Drugs 0.000 claims description 4
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 4
- 150000003839 salts Chemical class 0.000 claims description 4
- 230000001568 sexual effect Effects 0.000 claims description 4
- 238000002603 single-photon emission computed tomography Methods 0.000 claims description 4
- 229940124597 therapeutic agent Drugs 0.000 claims description 4
- 210000004962 mammalian cell Anatomy 0.000 claims description 3
- 229920006395 saturated elastomer Polymers 0.000 claims description 3
- FAIZUAWLKOHMOP-ZOIXLQFFSA-N (1s,3as,3bs,5ar,9ar,9bs,11as)-9a,11a-dimethyl-7-oxo-n-(1,1,1-trifluoro-2-phenylpropan-2-yl)-1,2,3,3a,3b,4,5,5a,6,9b,10,11-dodecahydroindeno[5,4-f]quinoline-1-carboxamide Chemical compound O=C([C@@H]1[C@]2(CC[C@@H]3[C@@]4(C)C=CC(=O)N[C@@H]4CC[C@H]3[C@@H]2CC1)C)NC(C)(C(F)(F)F)C1=CC=CC=C1 FAIZUAWLKOHMOP-ZOIXLQFFSA-N 0.000 claims description 2
- LKJPYSCBVHEWIU-KRWDZBQOSA-N (R)-bicalutamide Chemical compound C([C@@](O)(C)C(=O)NC=1C=C(C(C#N)=CC=1)C(F)(F)F)S(=O)(=O)C1=CC=C(F)C=C1 LKJPYSCBVHEWIU-KRWDZBQOSA-N 0.000 claims description 2
- LAMIXXKAWNLXOC-INIZCTEOSA-N (S)-HDAC-42 Chemical compound O=C([C@@H](C(C)C)C=1C=CC=CC=1)NC1=CC=C(C(=O)NO)C=C1 LAMIXXKAWNLXOC-INIZCTEOSA-N 0.000 claims description 2
- 125000001494 2-propynyl group Chemical group [H]C#CC([H])([H])* 0.000 claims description 2
- PAFKTGFSEFKSQG-PAASFTFBSA-N Galeterone Chemical compound C1=NC2=CC=CC=C2N1C1=CC[C@H]2[C@H](CC=C3[C@@]4(CC[C@H](O)C3)C)[C@@H]4CC[C@@]21C PAFKTGFSEFKSQG-PAASFTFBSA-N 0.000 claims description 2
- VMGWGDPZHXPFTC-HYBUGGRVSA-N Izonsteride Chemical compound CN([C@@H]1CCC2=C3)C(=O)CC[C@]1(C)C2=CC=C3SC(S1)=NC2=C1C=CC=C2CC VMGWGDPZHXPFTC-HYBUGGRVSA-N 0.000 claims description 2
- 239000002147 L01XE04 - Sunitinib Substances 0.000 claims description 2
- FJHHZXWJVIEFGJ-UHFFFAOYSA-N N-(3-methoxy-5-methyl-2-pyrazinyl)-2-[4-(1,3,4-oxadiazol-2-yl)phenyl]-3-pyridinesulfonamide Chemical compound COC1=NC(C)=CN=C1NS(=O)(=O)C1=CC=CN=C1C1=CC=C(C=2OC=NN=2)C=C1 FJHHZXWJVIEFGJ-UHFFFAOYSA-N 0.000 claims description 2
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 claims description 2
- GZOSMCIZMLWJML-VJLLXTKPSA-N abiraterone Chemical compound C([C@H]1[C@H]2[C@@H]([C@]3(CC[C@H](O)CC3=CC2)C)CC[C@@]11C)C=C1C1=CC=CN=C1 GZOSMCIZMLWJML-VJLLXTKPSA-N 0.000 claims description 2
- 229960000853 abiraterone Drugs 0.000 claims description 2
- HJBWBFZLDZWPHF-UHFFFAOYSA-N apalutamide Chemical compound C1=C(F)C(C(=O)NC)=CC=C1N1C2(CCC2)C(=O)N(C=2C=C(C(C#N)=NC=2)C(F)(F)F)C1=S HJBWBFZLDZWPHF-UHFFFAOYSA-N 0.000 claims description 2
- 229940120638 avastin Drugs 0.000 claims description 2
- 229960000397 bevacizumab Drugs 0.000 claims description 2
- 229960000997 bicalutamide Drugs 0.000 claims description 2
- 125000002837 carbocyclic group Chemical group 0.000 claims description 2
- 125000004432 carbon atom Chemical group C* 0.000 claims description 2
- 229960000978 cyproterone acetate Drugs 0.000 claims description 2
- UWFYSQMTEOIJJG-FDTZYFLXSA-N cyproterone acetate Chemical compound C1=C(Cl)C2=CC(=O)[C@@H]3C[C@@H]3[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(C)=O)(OC(=O)C)[C@@]1(C)CC2 UWFYSQMTEOIJJG-FDTZYFLXSA-N 0.000 claims description 2
- 229960003668 docetaxel Drugs 0.000 claims description 2
- 229960004199 dutasteride Drugs 0.000 claims description 2
- JWJOTENAMICLJG-QWBYCMEYSA-N dutasteride Chemical compound O=C([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)N[C@@H]4CC3)C)CC[C@@]21C)NC1=CC(C(F)(F)F)=CC=C1C(F)(F)F JWJOTENAMICLJG-QWBYCMEYSA-N 0.000 claims description 2
- 229960004671 enzalutamide Drugs 0.000 claims description 2
- WXCXUHSOUPDCQV-UHFFFAOYSA-N enzalutamide Chemical compound C1=C(F)C(C(=O)NC)=CC=C1N1C(C)(C)C(=O)N(C=2C=C(C(C#N)=CC=2)C(F)(F)F)C1=S WXCXUHSOUPDCQV-UHFFFAOYSA-N 0.000 claims description 2
- 229960004039 finasteride Drugs 0.000 claims description 2
- DBEPLOCGEIEOCV-WSBQPABSSA-N finasteride Chemical compound N([C@@H]1CC2)C(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H](C(=O)NC(C)(C)C)[C@@]2(C)CC1 DBEPLOCGEIEOCV-WSBQPABSSA-N 0.000 claims description 2
- 229960002074 flutamide Drugs 0.000 claims description 2
- MKXKFYHWDHIYRV-UHFFFAOYSA-N flutamide Chemical compound CC(C)C(=O)NC1=CC=C([N+]([O-])=O)C(C(F)(F)F)=C1 MKXKFYHWDHIYRV-UHFFFAOYSA-N 0.000 claims description 2
- 229950003400 galeterone Drugs 0.000 claims description 2
- 125000000623 heterocyclic group Chemical group 0.000 claims description 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 2
- 229950004319 izonsteride Drugs 0.000 claims description 2
- 125000004674 methylcarbonyl group Chemical group CC(=O)* 0.000 claims description 2
- 201000000585 muscular atrophy Diseases 0.000 claims description 2
- BLIJXOOIHRSQRB-PXYINDEMSA-N n-[(2s)-1-[3-(3-chloro-4-cyanophenyl)pyrazol-1-yl]propan-2-yl]-5-(1-hydroxyethyl)-1h-pyrazole-3-carboxamide Chemical compound C([C@H](C)NC(=O)C=1NN=C(C=1)C(C)O)N(N=1)C=CC=1C1=CC=C(C#N)C(Cl)=C1 BLIJXOOIHRSQRB-PXYINDEMSA-N 0.000 claims description 2
- 229960002653 nilutamide Drugs 0.000 claims description 2
- XWXYUMMDTVBTOU-UHFFFAOYSA-N nilutamide Chemical compound O=C1C(C)(C)NC(=O)N1C1=CC=C([N+]([O-])=O)C(C(F)(F)F)=C1 XWXYUMMDTVBTOU-UHFFFAOYSA-N 0.000 claims description 2
- WINHZLLDWRZWRT-ATVHPVEESA-N sunitinib Chemical compound CCN(CC)CCNC(=O)C1=C(C)NC(\C=C/2C3=CC(F)=CC=C3NC\2=O)=C1C WINHZLLDWRZWRT-ATVHPVEESA-N 0.000 claims description 2
- 229960001796 sunitinib Drugs 0.000 claims description 2
- 229950003684 zibotentan Drugs 0.000 claims description 2
- WMPQMBUXZHMEFZ-YJPJVVPASA-N turosteride Chemical compound CN([C@@H]1CC2)C(=O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H](C(=O)N(C(C)C)C(=O)NC(C)C)[C@@]2(C)CC1 WMPQMBUXZHMEFZ-YJPJVVPASA-N 0.000 claims 1
- 229950007816 turosteride Drugs 0.000 claims 1
- 238000000034 method Methods 0.000 description 33
- 206010068597 Bulbospinal muscular atrophy congenital Diseases 0.000 description 2
- 208000027747 Kennedy disease Diseases 0.000 description 2
- 208000006269 X-Linked Bulbo-Spinal Atrophy Diseases 0.000 description 2
- 239000003098 androgen Substances 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 206010004446 Benign prostatic hyperplasia Diseases 0.000 description 1
- NJLDNZLZBOZNAF-UHFFFAOYSA-N CC(C)(c(cc1)ccc1OCC(CO)O)c(cc1)cc(C)c1OCC(CCl)O Chemical compound CC(C)(c(cc1)ccc1OCC(CO)O)c(cc1)cc(C)c1OCC(CCl)O NJLDNZLZBOZNAF-UHFFFAOYSA-N 0.000 description 1
- OAYHGDVPFPSWMK-RNIVLKNTSA-N CC(C)(c(cc1)ccc1OC[C@H](CO)O)c(cc1)cc(I)c1OC/C(/O)=C/Cl Chemical compound CC(C)(c(cc1)ccc1OC[C@H](CO)O)c(cc1)cc(I)c1OC/C(/O)=C/Cl OAYHGDVPFPSWMK-RNIVLKNTSA-N 0.000 description 1
- KLORGFATABMJLF-QIYXJHPLSA-N CC(C)O/C=C(/COc1ccc(C(C)(C)c(cc2)cc(I)c2OC[C@H](CCl)O)cc1)\O Chemical compound CC(C)O/C=C(/COc1ccc(C(C)(C)c(cc2)cc(I)c2OC[C@H](CCl)O)cc1)\O KLORGFATABMJLF-QIYXJHPLSA-N 0.000 description 1
- IMPIZXGNGDNGAH-UHFFFAOYSA-N CC(C)OCC(COc1ccc(C(C)(C)c(cc2)cc(I)c2OCC(CCl)O)cc1)O Chemical compound CC(C)OCC(COc1ccc(C(C)(C)c(cc2)cc(I)c2OCC(CCl)O)cc1)O IMPIZXGNGDNGAH-UHFFFAOYSA-N 0.000 description 1
- IMPIZXGNGDNGAH-FIWHBWSRSA-N CC(C)OCC(COc1ccc(C(C)(C)c(cc2)cc(I)c2OC[C@@H](CCl)O)cc1)O Chemical compound CC(C)OCC(COc1ccc(C(C)(C)c(cc2)cc(I)c2OC[C@@H](CCl)O)cc1)O IMPIZXGNGDNGAH-FIWHBWSRSA-N 0.000 description 1
- GTSWMJBHLBAXRF-CBXNMNPBSA-N CC(C)OC[C@@H](COc1ccc(C(C)(C)c(cc2)cc(I)c2OC/C(/O)=C/Cl)cc1)O Chemical compound CC(C)OC[C@@H](COc1ccc(C(C)(C)c(cc2)cc(I)c2OC/C(/O)=C/Cl)cc1)O GTSWMJBHLBAXRF-CBXNMNPBSA-N 0.000 description 1
- IMPIZXGNGDNGAH-VQTJNVASSA-N CC(C)OC[C@H](COc1ccc(C(C)(C)c(cc2)cc(I)c2OC[C@H](CCl)O)cc1)O Chemical compound CC(C)OC[C@H](COc1ccc(C(C)(C)c(cc2)cc(I)c2OC[C@H](CCl)O)cc1)O IMPIZXGNGDNGAH-VQTJNVASSA-N 0.000 description 1
- 208000004403 Prostatic Hyperplasia Diseases 0.000 description 1
- 102000001708 Protein Isoforms Human genes 0.000 description 1
- 108010029485 Protein Isoforms Proteins 0.000 description 1
- 208000023958 prostate neoplasm Diseases 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361875556P | 2013-09-09 | 2013-09-09 | |
| US61/875,556 | 2013-09-09 | ||
| PCT/CA2014/000685 WO2015031984A1 (en) | 2013-09-09 | 2014-09-09 | Halogenated compounds for cancer imaging and treatment and methods for their use |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2016530285A JP2016530285A (ja) | 2016-09-29 |
| JP2016530285A5 true JP2016530285A5 (https=) | 2017-09-28 |
Family
ID=52627643
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016539372A Pending JP2016530285A (ja) | 2013-09-09 | 2014-09-09 | 癌の撮像及び治療のためのハロゲン化化合物、及びその使用方法 |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US9375496B2 (https=) |
| EP (1) | EP3044197B1 (https=) |
| JP (1) | JP2016530285A (https=) |
| KR (1) | KR20160054523A (https=) |
| AU (1) | AU2014317753A1 (https=) |
| CA (1) | CA2922192A1 (https=) |
| SG (1) | SG11201601431VA (https=) |
| WO (1) | WO2015031984A1 (https=) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2572596C2 (ru) | 2008-07-02 | 2016-01-20 | Бритиш Коламбиа Кэнсер Эйдженси Бранч | Терапевтические средства на основе производных диглицилиловых простых эфиров и способы их применения |
| AR079846A1 (es) | 2010-01-06 | 2012-02-22 | British Columbia Cancer Agency | Agentes terapeuticos derivados de bisfenol que contienen un grupo aquiral y su uso en el tratamiento del cancer |
| US9365510B2 (en) | 2012-04-16 | 2016-06-14 | British Columbia Cancer Agency Branch | Aziridine bisphenol ethers and related compounds and methods for their use |
| JP6884100B2 (ja) | 2015-01-13 | 2021-06-09 | ブリティッシュ コロンビア キャンサー エージェンシー ブランチ | がんの画像化及び治療用のヘテロ環式化合物ならびにそれらの使用方法 |
| US10471023B2 (en) | 2015-03-12 | 2019-11-12 | British Columbia Cancer Agency Branch | Bisphenol ether derivatives and methods for using the same |
| CA2929345A1 (en) * | 2015-09-02 | 2017-03-02 | British Columbia Cancer Agency Branch | Co-targeting androgen receptor splice variants and mtor signaling pathway for the treatment of castration-resistant prostate cancer |
| US20170298033A1 (en) * | 2016-04-15 | 2017-10-19 | The University Of British Columbia | Bisphenol derivatives and their use as androgen receptor activity modulators |
| WO2017210771A1 (en) * | 2016-06-06 | 2017-12-14 | British Columbia Cancer Agency Branch | Compounds and compositions for radiation therapy and methods of using the same |
| WO2019226991A1 (en) | 2018-05-25 | 2019-11-28 | Essa Pharma, Inc. | Androgen receptor modulators and methods for their use |
| MX2021004427A (es) | 2018-10-18 | 2021-11-12 | Univ British Columbia | Moduladores del receptor de andrógenos y métodos para su uso. |
| WO2020198712A1 (en) | 2019-03-28 | 2020-10-01 | Essa Pharma, Inc. | Pharmaceutical compositions and combinations comprising inhibitors of the androgen receptor and uses thereof |
| AU2021255723A1 (en) | 2020-04-17 | 2022-12-08 | Essa Pharma, Inc. | Solid forms of an N-terminal domain androgen receptor inhibitor and uses thereof |
| AU2021329906A1 (en) | 2020-08-18 | 2023-04-27 | Enviro Metals, LLC | Metal refinement |
| WO2023046283A1 (en) | 2021-09-22 | 2023-03-30 | Fundació Institut De Recerca Biomèdica (Irb Barcelona) | Compounds and their use in a method for modulating ar (androgen receptor) transcriptional activity |
Family Cites Families (57)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2571217A (en) | 1951-10-16 | Horace s | ||
| US2890189A (en) | 1954-06-14 | 1959-06-09 | Johnson & Son Inc S C | Alkali soluble resins and compositions containing the same |
| FR1389005A (fr) | 1963-01-09 | 1965-02-12 | Bayer Ag | Procédé perfectionné pour durcir des polyépoxydes |
| US4284574A (en) | 1979-06-15 | 1981-08-18 | Ciba-Geigy Corporation | Diglycidyl ethers of di-secondary alcohols, their preparation, and curable compositions containing them |
| US4369298A (en) | 1980-05-27 | 1983-01-18 | Tokuyama Soda Kabushiki Kaisha | Novel cured resin, process for production thereof, and lens composed of said resin from bis(alkyleneoxyphenyl)-diacrylate, bis(alkyleneoxyphenyl)diallyl ether, bis(alkyleneoxyphenyl)diallyl carbonate monomers |
| EP0056175B1 (en) | 1981-01-13 | 1985-05-02 | Teijin Limited | Ion-permeable composite membrane and its use in selective separation |
| PL135932B2 (en) | 1983-11-04 | 1986-01-31 | Politechnika Warszawska | Process for manufacturing polyfunctional polyols |
| PL141793B1 (en) | 1984-10-08 | 1987-08-31 | Politechnika Warszawska | Method of obtaining bisphenolic resins |
| US5753730A (en) | 1986-12-15 | 1998-05-19 | Mitsui Toatsu Chemicals, Inc. | Plastic lenses having a high-refractive index, process for the preparation thereof and casting polymerization process for preparing sulfur-containing urethane resin lens and lens prepared thereby |
| JPH0832844B2 (ja) | 1987-02-09 | 1996-03-29 | パイロツトインキ株式会社 | 筆記板用不透明性インキ |
| DE3852839T2 (de) | 1987-04-27 | 1995-06-22 | Mitsubishi Gas Chemical Co | Hitzehärtbare Harzzusammensetzung. |
| WO1988009782A1 (en) | 1987-06-01 | 1988-12-15 | The Dow Chemical Company | Process for making propargyl ethers of hydroxyaromatic compounds |
| US5155196A (en) | 1987-06-01 | 1992-10-13 | The Dow Chemical Company | Polymer resulting from the cure of a preformed chromene-containing mixture |
| DE3821585A1 (de) | 1987-09-13 | 1989-03-23 | Hoechst Ag | Positiv arbeitendes strahlungsempfindliches gemisch und daraus hergestelltes strahlungsempfindliches aufzeichnungsmaterial fuer hochenergetische strahlung |
| US4855184A (en) | 1988-02-02 | 1989-08-08 | Minnesota Mining And Manufacturing Company | Radiation-curable protective coating composition |
| DE3939760A1 (de) | 1989-12-01 | 1991-06-06 | Bayer Ag | Verfahren zur lackierung von kunststoffen, lackierte kunststoffe und die verwendung von hierzu geeigneten haftvermittlern |
| EP0515128A1 (en) | 1991-05-23 | 1992-11-25 | Konica Corporation | Silver halide color photographic light-sensitive material |
| JPH0649473A (ja) | 1992-08-04 | 1994-02-22 | Asahi Chem Ind Co Ltd | 冷媒組成物 |
| DE4323512A1 (de) | 1992-09-01 | 1994-04-28 | Agfa Gevaert Ag | Fotografisches Aufzeichnungsmaterial |
| JPH09176240A (ja) | 1995-12-27 | 1997-07-08 | Mitsubishi Chem Corp | 光重合性組成物 |
| ZA98900B (en) | 1997-02-07 | 1998-08-03 | Shell Int Research | Process for the manufacture of epoxy compounds |
| JPH10316803A (ja) | 1997-05-16 | 1998-12-02 | Teijin Chem Ltd | 難燃性樹脂組成物 |
| IL125840A (en) | 1997-08-22 | 2002-12-01 | Teijin Chemicals Ltd | Bromine compound production method |
| JPH11166087A (ja) | 1997-12-04 | 1999-06-22 | Teijin Chem Ltd | 難燃性樹脂組成物 |
| AU4494399A (en) | 1998-06-30 | 2000-01-24 | University Of British Columbia, The | Inhibitors of androgen-independent activation of androgen receptor |
| US6245117B1 (en) | 1998-08-07 | 2001-06-12 | Ipposha Oil Industries Co., Ltd. | Modifier of cellulose fibers and modification method of cellulose fibers |
| US6218430B1 (en) | 1998-08-24 | 2001-04-17 | Ligand Pharmaceuticals Incorporated | Vitamin D3 mimics |
| JP3795679B2 (ja) | 1998-09-01 | 2006-07-12 | 帝人化成株式会社 | 臭素化合物の製造方法 |
| AU775928B2 (en) | 1999-10-14 | 2004-08-19 | Bristol-Myers Squibb Company | Crystallographic structure of the androgen receptor ligand binding domain |
| US6534621B2 (en) | 2000-05-18 | 2003-03-18 | Dow Global Technologies Inc. | Process for manufacturing a hydroxyester derivative intermediate and epoxy resins prepared therefrom |
| US6472436B1 (en) | 2000-07-17 | 2002-10-29 | The Salk Institute For Biological Studies | Methods for protecting cells from amyloid toxicity and for inhibiting amyloid protein production |
| US6756400B2 (en) | 2000-08-31 | 2004-06-29 | Theravance, Inc. | Sodium channel modulators |
| US6646102B2 (en) | 2001-07-05 | 2003-11-11 | Dow Global Technologies Inc. | Process for manufacturing an alpha-dihydroxy derivative and epoxy resins prepared therefrom |
| US20030092724A1 (en) | 2001-09-18 | 2003-05-15 | Huaihung Kao | Combination sustained release-immediate release oral dosage forms with an opioid analgesic and a non-opioid analgesic |
| US7344700B2 (en) | 2002-02-28 | 2008-03-18 | University Of Tennessee Research Corporation | Radiolabeled selective androgen receptor modulators and their use in prostate cancer imaging and therapy |
| GB0324551D0 (en) | 2003-10-21 | 2003-11-26 | Karobio Ab | Novel compounds |
| CA2555597C (en) | 2004-02-13 | 2016-06-14 | The University Of British Columbia | Radiolabeled compounds and compositions, their precursors and methods for their production |
| JP2005325301A (ja) | 2004-05-17 | 2005-11-24 | Fuji Photo Film Co Ltd | セルロースアシレートドープ組成物、およびセルロースアシレートフィルム |
| EP1781280A2 (en) | 2004-08-18 | 2007-05-09 | Warner-Lambert Company LLC | Androgen modulators |
| JP2006208607A (ja) | 2005-01-26 | 2006-08-10 | Fuji Photo Film Co Ltd | パターン形成材料、並びにパターン形成装置及び永久パターン形成方法 |
| JP4753601B2 (ja) | 2005-03-23 | 2011-08-24 | 旭化成イーマテリアルズ株式会社 | 感光性組成物 |
| EP1717235A3 (en) | 2005-04-29 | 2007-02-28 | Bioprojet | Phenoxypropylpiperidines and -pyrrolidines and their use as histamine H3-receptor ligands |
| FR2885904B1 (fr) | 2005-05-19 | 2007-07-06 | Aventis Pharma Sa | Nouveaux derives du fluorene, compositions les contenant et utilisation |
| JP2007290980A (ja) | 2006-04-21 | 2007-11-08 | Shin Etsu Chem Co Ltd | 含フッ素（メタ）アクリル酸エステル |
| TW200819421A (en) | 2006-10-31 | 2008-05-01 | Univ Nat Chunghsing | The method of synthesizing biphenol A, BPA having di-alkoxyl group by using polycarbonate or its waste |
| KR20090115797A (ko) | 2007-02-20 | 2009-11-06 | 바스프 에스이 | 고굴절률 단량체, 이의 조성물 및 용도 |
| RU2572596C2 (ru) | 2008-07-02 | 2016-01-20 | Бритиш Коламбиа Кэнсер Эйдженси Бранч | Терапевтические средства на основе производных диглицилиловых простых эфиров и способы их применения |
| AR079975A1 (es) | 2010-01-06 | 2012-03-07 | British Columbia Cancer Agency | Agentes terapeuticos derivados de bisfenol u metodos para su uso, composiciones farmaceuticas y uso de los mismos |
| AR079846A1 (es) | 2010-01-06 | 2012-02-22 | British Columbia Cancer Agency | Agentes terapeuticos derivados de bisfenol que contienen un grupo aquiral y su uso en el tratamiento del cancer |
| EP2693875A4 (en) | 2011-04-08 | 2014-10-22 | British Columbia Cancer Agency | BISPHENOL COMPOUNDS AND METHOD FOR THEIR USE |
| WO2012145328A1 (en) | 2011-04-18 | 2012-10-26 | The University Of British Columbia | Dibenzylphenyl compounds and methods for their use |
| WO2012145330A1 (en) * | 2011-04-18 | 2012-10-26 | The University Of British Columbia | Fluorene-9-bisphenol compounds and methods for their use |
| WO2013028572A1 (en) | 2011-08-19 | 2013-02-28 | British Columbia Cancer Agency Branch | Fluorinated bisphenol ether compounds and methods for their use |
| WO2013028791A1 (en) | 2011-08-22 | 2013-02-28 | British Columbia Cancer Agency Branch | 18f compounds for cancer imaging and methods for their use |
| US9365510B2 (en) | 2012-04-16 | 2016-06-14 | British Columbia Cancer Agency Branch | Aziridine bisphenol ethers and related compounds and methods for their use |
| CN105358522A (zh) | 2013-05-10 | 2016-02-24 | 不列颠哥伦比亚癌症局分支机构 | 雄激素受体调节剂的酯衍生物及其使用方法 |
| US20150010469A1 (en) | 2013-07-03 | 2015-01-08 | British Columbia Cancer Agency Branch | Bisphenol ether compounds with novel bridging groups and methods for their use |
-
2014
- 2014-09-09 SG SG11201601431VA patent/SG11201601431VA/en unknown
- 2014-09-09 KR KR1020167008734A patent/KR20160054523A/ko not_active Withdrawn
- 2014-09-09 JP JP2016539372A patent/JP2016530285A/ja active Pending
- 2014-09-09 WO PCT/CA2014/000685 patent/WO2015031984A1/en not_active Ceased
- 2014-09-09 CA CA2922192A patent/CA2922192A1/en not_active Abandoned
- 2014-09-09 EP EP14843037.4A patent/EP3044197B1/en not_active Not-in-force
- 2014-09-09 AU AU2014317753A patent/AU2014317753A1/en not_active Abandoned
- 2014-09-09 US US14/481,727 patent/US9375496B2/en active Active
-
2016
- 2016-05-17 US US15/157,075 patent/US20160367707A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016530285A5 (https=) | ||
| JP2017516862A5 (https=) | ||
| JP2016518394A5 (https=) | ||
| AU2018360854B2 (en) | Modulators of the integrated stress pathway | |
| JP2018502120A5 (https=) | ||
| US20240173307A1 (en) | Modulators of the integrated stress pathway | |
| US20230144871A1 (en) | Modulators of the integrated stress pathway | |
| JP2018502867A5 (https=) | ||
| KR20190041471A (ko) | 케모카인 수용체 조절제 및 이의 용도 | |
| AU2018358157A1 (en) | Modulators of the integrated stress pathway | |
| US20160333114A1 (en) | Chimeric antigen receptor compositions | |
| JP7427655B2 (ja) | 精巣副腎残存腫瘍および卵巣副腎残存腫瘍を処置するための方法 | |
| WO2015183794A1 (en) | Tgr5 agonist complexes for treating diabetes and cancer | |
| JP2025081512A (ja) | 血液がんおよび固形がんの治療のためのキメラ抗原受容体改変ｔ細胞（ｃａｒ－ｔ） | |
| MX2021011811A (es) | Protacs que degradan el receptor de estrogeno. | |
| JP2015536997A5 (https=) | ||
| JP2015500225A5 (https=) | ||
| JP2015500887A5 (https=) | ||
| JP2019513795A5 (https=) | ||
| JP2017531619A5 (https=) | ||
| EP4446301A3 (en) | Heterocyclic compounds for cancer imaging and treatment and methods for their use | |
| US11602554B2 (en) | P53-targeting vaccines and pd-1 pathway inhibitors and methods of use thereof | |
| JP2017538712A5 (https=) | ||
| JP2018527301A5 (ja) | アジリジン含有ｄｎａアルキル化剤 | |
| RU2016119135A (ru) | Производные пиразолопиримидона или пирролотриазона, способ их получения и их фармацевтические применения |